Exploratory Study of Breast Cancer With ABY025

An Exploratory Study to Evaluate the Distribution of [111In]ABY-025 Uptake for SPECT Imaging in Subjects With Metastatic Breast Cancer

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01216033

Acronym

ABY0125

Enrollment

Registered

2010-10-07

Start date

2010-10-31

Completion date

2011-07-31

Last updated

2013-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Breast cancer, Diagnostics, HER2, Imaging, Metastases, SPECT, Imaging of metastases

Brief summary

The aim is to study if breast cancer metastases accumulate the newly developed HER2 binding molecule 111-In-ABY025 and if that shows whether the metastases express HER2.

Interventions

DRUG111-In-ABY-025

Intravenous injection of the agent

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* female age \>20 years * one or more known metastases localizations

Exclusion criteria

* other critical disease than breast cancer * age ≤ 20 years

Design outcomes

Primary

Measure	Time frame	Description
Imaging of metastases	One year	Imaging of breast cancer metastases using 111-In-ABY015 for SPECT

Secondary

Measure	Time frame
Can the new molecule be used for imaging in extended studies	October 2010 - June 2011

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026